Loading…
US healthcare technology company combining genomic sequencing and AI to help doctors personalize cancer and other disease treatment.
US healthcare technology company combining genomic sequencing and AI to help doctors personalize cancer and other disease treatment.
Most revenue is from genomic tests ordered by doctors and billed to insurers, hospitals or patients, paid per test, while data and software licences to drug developers add a second stream, often under multi-year deals. Buying Ambry Genetics in 2025 added hereditary-disease testing. Founder Eric Lefkofsky remains chief executive.
Moat: narrow (data, IP / patents, process know-how). Large proprietary multimodal cancer dataset feeds its AI models, a data advantage that compounds with scale.
Headquarters: Chicago, Illinois, US · Founded: 2015 · Employees: 3,800
Size Tempus AI (TEM) is a United States Information Technology company (Packaged Software) with a market value of $13.9B, the 636th largest of 3,117 United States companies the cockpit tracks. Shares closed at $76.05 on 6 Nov 2026.
Performance Over six months the shares gained 52.5%, against +28.8% for the median peer and -1.1% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 36.6% over the last twelve months (peer median +17.2%); the operating margin is -17.5% (peer median 21.7%).
Valuation It trades at 9.7× enterprise value to sales against a peer median of 5.3× (4th most expensive of 21).
Capital Return on invested capital runs 34.6 points below its cost of capital (18.5% WACC).
Credit Tempus AI has 2 bonds outstanding ($1.21B).
Short interest Short interest is 14.3% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.51B | $1.27B | $693M | $532M | $321M |
| Revenue growth | — | +83% | +30% | +66% | — |
| Gross profit | $958M | $782M | $369M | $278M | $122M |
| EBITDA | -$159M | -$136M | -$651M | -$163M | -$239M |
| Net income | -$189M | -$245M | -$706M | -$214M | -$290M |
| Free cash flow | -$138M | -$239M | -$211M | -$249M | -$187M |
| Capital expenditure | $42.3M | $27.3M | $22.1M | $34.6M | $18.4M |
| Total debt | $1.43B | $1.33B | $468M | $488M | $433M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Tempus AI TEM | $13.9B | +53% | +37% | -18% | 9.7× | n/a |
| Guardant Health GH | $20.2B | +58% | +43% | -40% | 17.7× | n/a |
| Natera NTRA | $44.8B | +60% | +38% | -11% | 16.2× | n/a |
| Caris Life Sciences CAI | $7.13B | +56% | +85% | 15% | 6.9× | 18.7% |
| NeoGenomics NEO | $2.18B | +88% | +11% | -6% | 3.2× | n/a |
| Labcorp LH | $29.8B | +45% | +6% | 11% | 2.5× | 13.9% |
| Veracyte VCYT | $1.94B | -40% | +17% | 17% | 2.9× | 15.1% |
| Myriad Genetics MYGN | $566M | +38% | -3% | -11% | 0.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TEM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.8% | +3.5% | 6th highest of 21 |
| 6-month return | +52.5% | +28.8% | 6th highest of 21 |
| Distance from 52-week high | -14.6% | -13.7% | 10th lowest of 21 |
| Revenue growth (TTM) | +36.6% | +17.2% | 3rd highest of 21 |
| Operating margin | -17.5% | 21.7% | 3rd lowest of 21 |
| EV / Sales | 9.7× | 5.3× | 4th most expensive of 21 |
| ROIC minus cost of capital | -34.6 pp | +5.4 pp | 2nd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tempus AI TEM | United States | $13.9B | +53% | +37% | -18% | 9.7× | n/a | n/a |
| Zhejiang Century Huatong 002602.SZ | China | $14.0B | -20% | +28% | 21% | 1.9× | -0.2% | +20.4% |
| Sage SGE.L | United Kingdom | $14.1B | +33% | +9% | 23% | 4.5× | 3.1% | +5.7% |
| DocuSign DOCU | United States | $14.5B | +62% | +9% | 12% | 4.1× | 12.9% | +17.2% |
| Manhattan Associates MANH | United States | $14.7B | +77% | +8% | 25% | 12.6× | 29.4% | +13.0% |
| Trimble TRMB | United States | $12.6B | -11% | +7% | 18% | 3.6× | 15.3% | +2.6% |
| Dynatrace DT | United States | $12.5B | +7% | +18% | 14% | 5.5× | 18.8% | +23.5% |
| JFrog FROG | United States | $12.5B | +43% | +26% | -13% | 19.4× | 37.7% | +28.7% |
| Evolution EVO.ST | Sweden | $15.8B | +33% | -3% | 57% | 6.6× | -0.3% | +31.2% |
| Beijing Kingsoft Office Software 688111.SS | China | $16.1B | -8% | +20% | 22% | 15.5× | 32.7% | +21.3% |
| Chime Financial CHYM | United States | $11.9B | +70% | +18% | -1% | 4.9× | 18.2% | +24.8% |
| Procore Technologies PCOR | United States | $11.4B | +41% | +16% | -1% | 7.3× | 19.9% | +27.0% |
| Circle Internet CRCL | United States | $17.3B | -40% | +26% | 13% | 5.2× | 23.2% | +52.7% |
| Capcom 9697.T | Japan | $11.0B | +25% | +21% | 41% | 6.8× | -2.2% | +15.4% |
| SailPoint SAIL | United States | $11.0B | +57% | +20% | -19% | 9.2× | 42.0% | +24.7% |
| F5, Inc. FFIV | United States | $17.7B | -12% | +11% | 24% | 4.8× | 9.7% | +5.6% |
| Gen Digital GEN | United States | $17.7B | +32% | +17% | 43% | 4.8× | 1.8% | +14.4% |
| SS&C Technologies SSNC | United States | $18.2B | +13% | +9% | 24% | 3.8× | 6.9% | +6.1% |
| Paycom Software PAYC | United States | $10.5B | +73% | +9% | 30% | 5.2× | 3.3% | +19.5% |
| Wisetech Global WTC.AX | Australia | $10.3B | +15% | +71% | 31% | 8.5× | 30.1% | +32.3% |
| Figma FIG | United States | $10.0B | -9% | +43% | -124% | 6.6× | 22.2% | +43.4% |
Tempus AI has 2 bonds outstanding with $1.21B face value.